マントル細胞リンパ腫治療薬の世界市場レポート 2025年

マントル細胞リンパ腫治療薬市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR8.0％で35億6,000万米ドルに成長します。予測期間の成長は、標的療法の進歩、免疫療法の革新、個別化医療の動向、世界の市場拡大、罹患率の増加に起因すると考えられます。予測期間における主な動向には、免疫療法の進歩、精密医療とバイオマーカー開発、特定の経路に対する標的療法、併用療法、人工知能（AI）の統合などが含まれます。

マントル細胞リンパ腫の有病率の増加が予想されることから、マントル細胞リンパ腫治療薬市場の拡大が見込まれます。マントル細胞リンパ腫（MCL）は非ホジキンリンパ腫（NHL）の一種で、リンパ系に影響を及ぼします。マントル細胞リンパ腫の治療薬は、患者の転帰の改善、生存期間の延長、疾病負担の軽減につながる病態を治療・管理することにより、この疾患の蔓延を抑制する上で極めて重要な役割を果たしています。2022年12月現在、米国連邦政府が運営する米国の生物医学図書館である国立医学図書館は、マントル細胞リンパ腫の年間発生率を20万人当たり1例と報告しており、非ホジキンリンパ腫全体の5％に寄与しています。このように、マントル細胞リンパ腫の有病率の上昇は、マントル細胞リンパ腫治療薬市場の成長の起爆剤となっています。

遠隔医療サービスの利用可能性の増加がマントル細胞リンパ腫治療薬市場を押し上げようとしています。遠隔医療サービスは、通信技術を利用してヘルスケアサービスや医療相談を遠隔で提供するものです。遠隔医療サービスの急増は、マントル細胞リンパ腫治療薬市場におけるアクセシビリティ、効率性、患者エンゲージメントを向上させ、全体的なケアと治療成果の改善に貢献します。米国の政府機関である疾病対策予防センター（Centers for Disease Control and Prevention）の2022年10月の報告によると、成人の37.0％が2021年の過去12ヵ月間に遠隔医療サービスを利用したと報告しています。注目すべきは、男性（31.7％）に比べて女性の遠隔医療利用率が高いこと（42.0％）です。さらに、年齢と遠隔医療利用には正の相関関係が見られ、成人の遠隔医療利用率は18～29歳の29.4％から65歳以上の43.3％に上昇しました。その結果、遠隔医療サービスの成長がマントル細胞リンパ腫治療薬市場を促進しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界マントル細胞リンパ腫治療薬PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界のマントル細胞リンパ腫治療薬市場：成長率分析
• 世界のマントル細胞リンパ腫治療薬市場の実績：規模と成長, 2019-2024
• 世界のマントル細胞リンパ腫治療薬市場の予測：規模と成長, 2024-2029, 2034F
• 世界マントル細胞リンパ腫治療薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のマントル細胞リンパ腫治療薬市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 併用療法
• 単独療法
• 世界のマントル細胞リンパ腫治療薬市場作用機序別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ブルトンチロシンキナーゼ阻害剤
• アルキル化剤
• デオキシリボ核酸合成阻害剤
• 微小管阻害剤
• モノクローナル抗体
• その他のメカニズム
• 世界のマントル細胞リンパ腫治療薬市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オーラル
• 非経口
• 世界のマントル細胞リンパ腫治療薬市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• 調査機関
• その他の用途
• 世界のマントル細胞リンパ腫治療薬市場、併用療法のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 化学療法の組み合わせ
• 標的療法の組み合わせ
• 免疫療法の組み合わせ
• 世界のマントル細胞リンパ腫治療薬市場、単剤療法のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 単剤化学療法
• 標的療法単剤療法
• 免疫療法単独療法

第7章 地域別・国別分析

• 世界のマントル細胞リンパ腫治療薬市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のマントル細胞リンパ腫治療薬市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• マントル細胞リンパ腫治療薬市場：競合情勢
• マントル細胞リンパ腫治療薬市場：企業プロファイル
  • AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
  • Celgene Corporation Overview, Products and Services, Strategy and Financial Analysis
  • Johnson & Johnson Consumer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Takeda Pharmaceutical Company Limited Overview, Products and Services, Strategy and Financial Analysis
  • Bayer Aktiengesellschaft Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Eli Lilly and Company
• Amgen Inc.
• GlaxoSmithKline plc
• Kite Pharma Inc.
• Gilead Sciences Inc.
• AbbVie Inc.
• Bristol-Myers Squibb Company
• Novartis AG
• Merck & Co. Inc.
• Massive Bio Inc.
• Juno Therapeutics Inc.
• Nurix Therapeutics Inc.
• Janssen Biotech Inc.
• TG Therapeutics Inc.
• F. Hoffmann-La Roche AG

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• マントル細胞リンパ腫治療薬市場2029：新たな機会を提供する国
• マントル細胞リンパ腫治療薬市場2029：新たな機会を提供するセグメント
• マントル細胞リンパ腫治療薬市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Mantle cell lymphoma therapeutics pertains to the treatment approaches and strategies employed for the management of mantle cell lymphoma (MCL), a subtype of non-Hodgkin lymphoma characterized by abnormal B-cell growth in the lymphatic system. These treatments utilize targeted strategies, including BTK and BCL2 inhibitors, known for their enduring therapeutic effects.

The primary categories of mantle cell lymphoma therapeutics encompass combination therapy and monotherapy. Combination therapy involves the simultaneous utilization of multiple treatments or medications to enhance their effectiveness in addressing a specific condition or disease. In the context of mantle cell lymphoma therapeutics, combination therapy integrates various approaches such as chemotherapy, targeted therapy, and immunotherapy to optimize treatment outcomes and enhance patient well-being. The drugs function through Bruton tyrosine kinase inhibitors, alkylating agents, deoxyribonucleic acid synthesis inhibitors, microtubule inhibitors, monoclonal antibodies, among others, and can be administered through oral and parenteral routes. These therapeutic interventions find application in hospitals, research institutes, and other healthcare settings.

The mantle cell lymphoma therapeutics market research report is one of a series of new reports from The Business Research Company that provides mantle cell lymphoma therapeutics market statistics, including the mantle cell lymphoma therapeutics industry global market size, regional shares, competitors with a mantle cell lymphoma therapeutics market share, detailed mantle cell lymphoma therapeutics market segments, market trends, and opportunities, and any further data you may need to thrive in the mantle cell lymphoma therapeutics industry. This mantle cell lymphoma therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The mantle cell lymphoma therapeutics market size has grown strongly in recent years. It will grow from$2.42 billion in 2024 to $2.62 billion in 2025 at a compound annual growth rate (CAGR) of 8.2%. The growth in the historic period can be attributed to advances in research, clinical trial success, improved diagnostic tools, treatment access expansion, collaborative research initiatives

The mantle cell lymphoma therapeutics market size is expected to see strong growth in the next few years. It will grow to $3.56 billion in 2029 at a compound annual growth rate (CAGR) of 8.0%. The growth in the forecast period can be attributed to targeted therapies advancements, immunotherapy innovations, personalized medicine trends, global market expansion, increasing incidence rates. Major trends in the forecast period include immunotherapy advancements, precision medicine and biomarker development, targeted therapies for specific pathways, combination therapies, integration of artificial intelligence (AI).

The anticipated increase in the prevalence of mantle cell lymphoma is set to drive the expansion of the mantle cell lymphoma therapeutics market. Mantle cell lymphoma (MCL) represents a form of non-Hodgkin lymphoma (NHL), impacting the lymphatic system. Therapeutics for mantle cell lymphoma play a pivotal role in curbing the prevalence of the disease by treating and managing the condition, leading to improved patient outcomes, prolonged survival, and diminished disease burden. As of December 2022, the National Library of Medicine, a US-based biomedical library operated by the United States Federal Government, reported an annual incidence of one case of mantle cell lymphoma per 200,000 people, contributing to 5% of all non-Hodgkin lymphomas. Thus, the escalating prevalence of mantle cell lymphoma is a catalyst for the growth of the mantle cell lymphoma therapeutics market.

The increasing availability of telemedicine services is poised to elevate the mantle cell lymphoma therapeutics market. Telemedicine services involve delivering healthcare services and medical consultations remotely, utilizing telecommunications technology. The surge in telemedicine services enhances accessibility, efficiency, and patient engagement within the mantle cell lymphoma therapeutics market, contributing to overall improved care and treatment outcomes. According to an October 2022 report from the Centers for Disease Control and Prevention, a US-based government agency, 37.0% of adults reported having utilized telemedicine services in the previous 12 months of 2021. Notably, women exhibited a higher likelihood of telemedicine usage (42.0%) compared to men (31.7%). Additionally, a positive correlation was observed between age and telemedicine usage, with the percentage of adults engaging in telemedicine rising from 29.4% among those aged 18-29 to 43.3% among adults aged 65 and above. Consequently, the growth of telemedicine services is propelling the mantle cell lymphoma therapeutics market.

A significant trend gaining traction in the mantle cell lymphoma therapeutics market is the development of targeted therapy drugs. Major players in the market are actively involved in creating new drugs for targeted therapy to maintain their market standing. For instance, in March 2023, AstraZeneca plc., a UK-based pharmaceutical company, received approval for Calquence (acalabrutinib) from the National Medical Products Administration (NMPA) to market the drug in China for adult patients with mantle cell lymphoma (MCL). Calquence (acalabrutinib) is a selective Bruton's tyrosine kinase (BTK) inhibitor, offering a tolerable and effective new treatment option for controlling mantle cell lymphoma.

Companies operating in the mantle cell lymphoma therapeutics market are innovating by developing products such as kinase inhibitors to broaden their customer bases, increase sales, and boost revenue. A kinase inhibitor is a pharmaceutical agent that interferes with the activity of enzymes called kinases. In January 2023, Eli Lilly and Company, a US-based pharmaceutical company, announced FDA approval for Jaypirca (pirtobrutinib, 100 mg & 50 mg tablets), indicated for adult patients experiencing a recurrence or resistance to prior treatments for mantle cell lymphoma (MCL). Jaypirca, a highly selective kinase inhibitor, utilizes a unique binding mechanism and stands out for its ability to reestablish BTK inhibition in patients with mantle cell lymphoma who have undergone prior treatment with covalent BTK inhibitors.

In August 2022, AstraZeneca plc, a UK-based pharmaceutical and biotechnology company, acquired TeneoTwo Inc. for $1.3 billion. This strategic acquisition aims to diversify and strengthen AstraZeneca's product portfolio by incorporating hematology and mantle cell lymphoma therapeutic drugs. TeneoTwo Inc., a US-based biotechnology company focusing on medicine development for oncology, operates in the mantle cell lymphoma therapeutics market.

Major companies operating in the mantle cell lymphoma therapeutics market include AstraZeneca plc, Celgene Corporation, Johnson & Johnson Consumer Inc., Takeda Pharmaceutical Company Limited, Bayer Aktiengesellschaft, Eli Lilly and Company, Amgen Inc., GlaxoSmithKline plc, Kite Pharma Inc., Gilead Sciences Inc., AbbVie Inc., Bristol-Myers Squibb Company, Novartis AG, Merck & Co. Inc., Massive Bio Inc., Juno Therapeutics Inc., Nurix Therapeutics Inc., Janssen Biotech Inc., TG Therapeutics Inc., F. Hoffmann-La Roche AG, Astex Pharmaceuticals Inc., Astellas Pharma Inc., BeiGene Ltd., Daiichi Sankyo Company Limited, Eisai Co. Ltd., Exelixis Inc., Hutchison China MediTech Limited, Incyte Corporation, Ionis Pharmaceuticals Inc.

North America was the largest region in the global mantle cell lymphoma therapeutics market in 2024. The regions covered in the mantle cell lymphoma therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the mantle cell lymphoma therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The mantle cell lymphoma therapeutics market includes revenues earned by entities by brukinsa (zanubrutinib), imbruvica (ibrutinib), Revlimid (lenalidomide), and tecartus (brexucabtagene autoleucel). The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Mantle Cell Lymphoma Therapeutics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on mantle cell lymphoma therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for mantle cell lymphoma therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The mantle cell lymphoma therapeutics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Combination Therapy; Monotherapy
• 2) By Mechanism of Action: Bruton Tyrosine Kinase Inhibitors; Alkylating Agents; Deoxyribonucleic Acid Synthesis Inhibitors; Microtubule Inhibitors; Monoclonal Antibodies; Other Mechanisms
• 3) By Route of Administration: Oral; Parenteral
• 4) By Application: Hospital; Research Institute; Other Applications
• Subsegments:
• 1) By Combination Therapy: Chemotherapy Combinations; Targeted Therapy Combinations; Immunotherapy Combinations
• 2) By Monotherapy: Single-Agent Chemotherapy; Targeted Therapy Monotherapy; Immunotherapy Monotherapy
• Companies Mentioned: AstraZeneca plc; Celgene Corporation; Johnson & Johnson Consumer Inc.; Takeda Pharmaceutical Company Limited; Bayer Aktiengesellschaft
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Mantle Cell Lymphoma Therapeutics Market Characteristics

3. Mantle Cell Lymphoma Therapeutics Market Trends And Strategies

4. Mantle Cell Lymphoma Therapeutics Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Mantle Cell Lymphoma Therapeutics Growth Analysis And Strategic Analysis Framework

• 5.1. Global Mantle Cell Lymphoma Therapeutics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Mantle Cell Lymphoma Therapeutics Market Growth Rate Analysis
• 5.4. Global Mantle Cell Lymphoma Therapeutics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Mantle Cell Lymphoma Therapeutics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Mantle Cell Lymphoma Therapeutics Total Addressable Market (TAM)

6. Mantle Cell Lymphoma Therapeutics Market Segmentation

• 6.1. Global Mantle Cell Lymphoma Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Combination Therapy
• Monotherapy
• 6.2. Global Mantle Cell Lymphoma Therapeutics Market, Segmentation By Mechanism of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Bruton Tyrosine Kinase Inhibitors
• Alkylating Agents
• Deoxyribonucleic Acid Synthesis Inhibitors
• Microtubule Inhibitors
• Monoclonal Antibodies
• Other Mechanisms
• 6.3. Global Mantle Cell Lymphoma Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Parenteral
• 6.4. Global Mantle Cell Lymphoma Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital
• Research Institute
• Other Applications
• 6.5. Global Mantle Cell Lymphoma Therapeutics Market, Sub-Segmentation Of Combination Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Chemotherapy Combinations
• Targeted Therapy Combinations
• Immunotherapy Combinations
• 6.6. Global Mantle Cell Lymphoma Therapeutics Market, Sub-Segmentation Of Monotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Single-Agent Chemotherapy
• Targeted Therapy Monotherapy
• Immunotherapy Monotherapy

7. Mantle Cell Lymphoma Therapeutics Market Regional And Country Analysis

• 7.1. Global Mantle Cell Lymphoma Therapeutics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Mantle Cell Lymphoma Therapeutics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Mantle Cell Lymphoma Therapeutics Market

• 8.1. Asia-Pacific Mantle Cell Lymphoma Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Mantle Cell Lymphoma Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Mantle Cell Lymphoma Therapeutics Market, Segmentation By Mechanism of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Mantle Cell Lymphoma Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Mantle Cell Lymphoma Therapeutics Market

• 9.1. China Mantle Cell Lymphoma Therapeutics Market Overview
• 9.2. China Mantle Cell Lymphoma Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Mantle Cell Lymphoma Therapeutics Market, Segmentation By Mechanism of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Mantle Cell Lymphoma Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Mantle Cell Lymphoma Therapeutics Market

• 10.1. India Mantle Cell Lymphoma Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Mantle Cell Lymphoma Therapeutics Market, Segmentation By Mechanism of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Mantle Cell Lymphoma Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Mantle Cell Lymphoma Therapeutics Market

• 11.1. Japan Mantle Cell Lymphoma Therapeutics Market Overview
• 11.2. Japan Mantle Cell Lymphoma Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Mantle Cell Lymphoma Therapeutics Market, Segmentation By Mechanism of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Mantle Cell Lymphoma Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Mantle Cell Lymphoma Therapeutics Market

• 12.1. Australia Mantle Cell Lymphoma Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Mantle Cell Lymphoma Therapeutics Market, Segmentation By Mechanism of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Mantle Cell Lymphoma Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Mantle Cell Lymphoma Therapeutics Market

• 13.1. Indonesia Mantle Cell Lymphoma Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Mantle Cell Lymphoma Therapeutics Market, Segmentation By Mechanism of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Mantle Cell Lymphoma Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Mantle Cell Lymphoma Therapeutics Market

• 14.1. South Korea Mantle Cell Lymphoma Therapeutics Market Overview
• 14.2. South Korea Mantle Cell Lymphoma Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Mantle Cell Lymphoma Therapeutics Market, Segmentation By Mechanism of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Mantle Cell Lymphoma Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Mantle Cell Lymphoma Therapeutics Market

• 15.1. Western Europe Mantle Cell Lymphoma Therapeutics Market Overview
• 15.2. Western Europe Mantle Cell Lymphoma Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Mantle Cell Lymphoma Therapeutics Market, Segmentation By Mechanism of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Mantle Cell Lymphoma Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Mantle Cell Lymphoma Therapeutics Market

• 16.1. UK Mantle Cell Lymphoma Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Mantle Cell Lymphoma Therapeutics Market, Segmentation By Mechanism of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Mantle Cell Lymphoma Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Mantle Cell Lymphoma Therapeutics Market

• 17.1. Germany Mantle Cell Lymphoma Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Mantle Cell Lymphoma Therapeutics Market, Segmentation By Mechanism of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Mantle Cell Lymphoma Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Mantle Cell Lymphoma Therapeutics Market

• 18.1. France Mantle Cell Lymphoma Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Mantle Cell Lymphoma Therapeutics Market, Segmentation By Mechanism of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Mantle Cell Lymphoma Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Mantle Cell Lymphoma Therapeutics Market

• 19.1. Italy Mantle Cell Lymphoma Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Mantle Cell Lymphoma Therapeutics Market, Segmentation By Mechanism of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Mantle Cell Lymphoma Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Mantle Cell Lymphoma Therapeutics Market

• 20.1. Spain Mantle Cell Lymphoma Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Mantle Cell Lymphoma Therapeutics Market, Segmentation By Mechanism of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Mantle Cell Lymphoma Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Mantle Cell Lymphoma Therapeutics Market

• 21.1. Eastern Europe Mantle Cell Lymphoma Therapeutics Market Overview
• 21.2. Eastern Europe Mantle Cell Lymphoma Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Mantle Cell Lymphoma Therapeutics Market, Segmentation By Mechanism of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Mantle Cell Lymphoma Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Mantle Cell Lymphoma Therapeutics Market

• 22.1. Russia Mantle Cell Lymphoma Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Mantle Cell Lymphoma Therapeutics Market, Segmentation By Mechanism of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Mantle Cell Lymphoma Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Mantle Cell Lymphoma Therapeutics Market

• 23.1. North America Mantle Cell Lymphoma Therapeutics Market Overview
• 23.2. North America Mantle Cell Lymphoma Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Mantle Cell Lymphoma Therapeutics Market, Segmentation By Mechanism of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Mantle Cell Lymphoma Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Mantle Cell Lymphoma Therapeutics Market

• 24.1. USA Mantle Cell Lymphoma Therapeutics Market Overview
• 24.2. USA Mantle Cell Lymphoma Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Mantle Cell Lymphoma Therapeutics Market, Segmentation By Mechanism of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Mantle Cell Lymphoma Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Mantle Cell Lymphoma Therapeutics Market

• 25.1. Canada Mantle Cell Lymphoma Therapeutics Market Overview
• 25.2. Canada Mantle Cell Lymphoma Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Mantle Cell Lymphoma Therapeutics Market, Segmentation By Mechanism of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Mantle Cell Lymphoma Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Mantle Cell Lymphoma Therapeutics Market

• 26.1. South America Mantle Cell Lymphoma Therapeutics Market Overview
• 26.2. South America Mantle Cell Lymphoma Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Mantle Cell Lymphoma Therapeutics Market, Segmentation By Mechanism of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Mantle Cell Lymphoma Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Mantle Cell Lymphoma Therapeutics Market

• 27.1. Brazil Mantle Cell Lymphoma Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Mantle Cell Lymphoma Therapeutics Market, Segmentation By Mechanism of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Mantle Cell Lymphoma Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Mantle Cell Lymphoma Therapeutics Market

• 28.1. Middle East Mantle Cell Lymphoma Therapeutics Market Overview
• 28.2. Middle East Mantle Cell Lymphoma Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Mantle Cell Lymphoma Therapeutics Market, Segmentation By Mechanism of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Mantle Cell Lymphoma Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Mantle Cell Lymphoma Therapeutics Market

• 29.1. Africa Mantle Cell Lymphoma Therapeutics Market Overview
• 29.2. Africa Mantle Cell Lymphoma Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Mantle Cell Lymphoma Therapeutics Market, Segmentation By Mechanism of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Mantle Cell Lymphoma Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Mantle Cell Lymphoma Therapeutics Market Competitive Landscape And Company Profiles

• 30.1. Mantle Cell Lymphoma Therapeutics Market Competitive Landscape
• 30.2. Mantle Cell Lymphoma Therapeutics Market Company Profiles
  • 30.2.1. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Celgene Corporation Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Johnson & Johnson Consumer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Takeda Pharmaceutical Company Limited Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Bayer Aktiengesellschaft Overview, Products and Services, Strategy and Financial Analysis

31. Mantle Cell Lymphoma Therapeutics Market Other Major And Innovative Companies

• 31.1. Eli Lilly and Company
• 31.2. Amgen Inc.
• 31.3. GlaxoSmithKline plc
• 31.4. Kite Pharma Inc.
• 31.5. Gilead Sciences Inc.
• 31.6. AbbVie Inc.
• 31.7. Bristol-Myers Squibb Company
• 31.8. Novartis AG
• 31.9. Merck & Co. Inc.
• 31.10. Massive Bio Inc.
• 31.11. Juno Therapeutics Inc.
• 31.12. Nurix Therapeutics Inc.
• 31.13. Janssen Biotech Inc.
• 31.14. TG Therapeutics Inc.
• 31.15. F. Hoffmann-La Roche AG

32. Global Mantle Cell Lymphoma Therapeutics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Mantle Cell Lymphoma Therapeutics Market

34. Recent Developments In The Mantle Cell Lymphoma Therapeutics Market

35. Mantle Cell Lymphoma Therapeutics Market High Potential Countries, Segments and Strategies

• 35.1 Mantle Cell Lymphoma Therapeutics Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Mantle Cell Lymphoma Therapeutics Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Mantle Cell Lymphoma Therapeutics Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer